drugset / Trial / NCT02597712
YF476 in Barrett's Esophagus
Phase 2
Completed
27 enrolled
Trio Medicines Ltd.
Columbia University · collabUniversity of Cambridge · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2, randomised, double-blind, out-patient trial to determine if YF476 is a safe and effective treatment in patients with Barrett's esophagus.
Timeline
- Start
- 2013-05-15
- Primary completion
- 2017-11-28
- Completion
- 2017-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | netazepide | Protein / enzyme biologic | 25 mg | — |